INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2024

Omega-3 fatty acid supplementation has very uncertain effects on walking distance, quality of life, and clinical outcomes in intermittent claudication.

A systematic review evaluated 15 RCTs (1,830 participants) examining omega-3 fatty acids versus placebo or non-omega-3 fatty acids for intermittent claudication. Omega-3 supplementation may result in little to no effect on pain-free walking distance (MD 1.01 m, 95% CI -34.23 to 36.24; 3 studies, 147 participants) or maximal walking distance (MD -4.18 m, 95% CI -37.10 to 28.74; 3 studies, 164 participants). Ankle-brachial index also showed little to no difference (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants), and meta-analyses showed no differences in cholesterol, triglycerides, or blood pressure. The evidence for walking outcomes, quality of life, and limb events was rated very low certainty, and majority of the included studies had an unclear risk of bias.

Study type
Systematic review and meta-analysis of randomized controlled trials
Who was studied
1,830 participants with intermittent claudication across 15 RCTs
What was measured
Quality of life, pain-free and maximal walking distance, ankle-brachial index, revascularization, amputation, adverse events, lipid levels, blood pressure, and mortality

THE PAPER

Omega-3 fatty acids for intermittent claudication.

Mohammady M, Brown T, Radmehr M, Shamsoddin E, Janani L. Cochrane Database Syst Rev, 2024.

PubMed 39470212 ↗DOI 10.1002/14651858.cd003833.pub3 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.